SCHEMBL6892003

SCHEMBL6892003

CC(Cl)c1ccc(-n2ccnc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.59
LMNA P02545 1/20 0.55
MAPT P10636 1/20 0.55
ENPP2 Q13822 1/20 0.55
MKNK1 Q9BUB5 1/20 0.55
MKNK2 Q9HBH9 1/20 0.55
CYP3A4 P08684 4/20 0.53
KMT2A Q03164 3/20 0.51
MEN1 O00255 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
BAZ2B Q9UIF8 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
CYP19A1 P11511 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
CYP51A1 Q16850 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801703 0.85 NOTUM (0.63) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL8047855 0.82 LMNA (0.55) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL6895118 0.82 ENPP2 (0.59) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL8278915 0.82 LMNA (0.59) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL2532397 0.80 LMNA (0.78) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL10311213 0.79 CYP3A4 (0.53) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL14438346 0.78 TDP1 (0.56) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL9364392 0.78 LMNA (0.50) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL27513744 0.78 CYP3A4 (0.51) NOTUMLMNAMAPTENPP2MKNK1
SCHEMBL27513743 0.78 CYP3A4 (0.59) NOTUMLMNAMAPTENPP2MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6680312-B2 FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-20 US disclosed
US-20020193382-A1 Sulfonamide derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2002-12-19 US disclosed
US-6403595-B1 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-06-11 US disclosed
EP-1054005-A1 SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193382-A1 Sulfonamide derivatives, their production and use F12, F11, F2 NOTUM 862/4885LMNA 832/4885MAPT 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.